Consequently, multi-marker strategies combining NT-proBNP with markers of fibrosis or inflammation (e.g., sST2 or Gal-3) are emerging as a more accurate and personalized approach to HF phenotyping and risk prediction (Figure 2). Here, NPPB is linked to hydrops fetalis.